기업 프로필 · Healthcare

Becton Dickinson and Company

BDX · 미국
거래소
미국
국가 / 지역
USA
상장일
1987년 1월 1일
직원 수
60,000
웹사이트
www.bd.com
현재가
$143.98
실시간 · 2026년 6월 18일
베일리 성장 점수
40/100
다소 약함
내재가치 · 3단계 구간 현재가 $143.98 실시간 · 보수적 구간과 적정 구간 사이

종합 밸류에이션 구간 · 보수적 $108–$125 / 적정 $154–$178 / 낙관적 $217–$249. $143.98 기준, 보수적 구간과 적정 구간 사이.

보고서 발행 시 $147.63(2026년 5월 24일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

시가총액US$390.19억
매출 (TTM)US$222.27억
EBITDAUS$61.57억
순이익률5.12%
ROE6.67%
PER (TTM)24.71
선행 PER10.49
PEG1.11
EPSUS$5.73
배당수익률2.88%
52주 범위US$125.21 – US$184.86
애널리스트 목표주가US$180.69
애널리스트 평가3.8 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.